Villeneuve-d'Ascq, France · Founded 2020 · Privately Held (backing)
Operator of a biotechnology platform intended to treat resistant tumors using proprietary photosensitizing molecules paired with advanced laser light technologies. Hemerion Therapeutics is based in Villeneuve-d'Ascq, France and was founded in 2020. Its last reported valuation was $26.2 million in May 2025. It has raised $14.2 million.
Last reported valuation
$26.2M
Oct 2026
Priced at
—
Total raised
$14.2M
Last round
—
No prints on record
No secondary trades in Hemerion Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Hemerion Therapeutics with a free account
·Watch Hemerion Therapeutics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Hemerion Therapeutics stock.
